ArticleJournal of inflammation research2025
Xuebijing Injection Alleviates Sepsis-Induced Acute Lung Injury by Inhibition of Cell Apoptosis and Inflammation Through the Hippo Pathway.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The "habitat-phytochemistry-pharmacological effect" nexus: a multidimensional review of ethnomedicinalFrontiers in pharmacology · 2026Review
- Pharmacological actions and applications of safflower flavonoids.Frontiers in nutrition · 2025Review
- Paeoniflorin attenuates sepsis-induced liver injury by reprogramming macrophage polarization via the TLR4/NF-κB pathway.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a critical complication of sepsis, strongly associated with poor prognosis. Xuebijing (XBJ) injection, a standardized multi-herbal formulation containing five active components (safflower, red peony, Chuanxiong, Salvia miltiorrhiza, and Angelica sinensis), has demonstrated clinical efficacy in sepsis management through its multimodal pharmacological actions. While XBJ is increasingly used as an adjunctive therapy for sepsis-induced ALI/ARDS, its specific protective mechanisms remain incompletely understood. The purpose of this study was to evaluate the improvement effect of XBJ injection on ALI in sepsis and its undefined molecular mechanism. Methods: Sepsis-induced ALI (SALI) murine animal model was established in rats by cecum ligation and puncture (CLP), and these rats were treated with or without XBJ injection. Lung injury across different groups was assessed by HE staining, W/D ratio, and BALF analysis. ZO-1 and CD31 immunofluorescence were used to evaluate endothelial damage. To illustrate the mechanism of the protective effect of XBJ on SALI, human umbilical vein endothelial cells (HUVECs) stimulated with lipopolysaccharide (LPS) were used to establish an in vitro endothelial inflammation model. Inflammatory cytokines and apoptotic proteins were measured in LPS-stimulated HUVECs to evaluate endothelial inflammation. Lung tissue transcriptomic analysis was performed to explore downstream pathway, and key Hippo pathway related proteins were assessed in both rat lung tissue and HUVECs. Results: In SALI animal models, treatment with XBJ significantly alleviated lung injury. Meanwhile, a substantial amelioration of endothelial damage was observed. In vitro, XBJ substantially mitigated apoptosis and inflammatory response of LPS stimulated HUVECs. Meanwhile, transcriptomic analysis revealed that XBJ significantly upregulates the gene expression of the Hippo-related signaling pathway, and we further validated these findings in both rat lung tissues and HUVECs. Conclusion: Our study establishes the preventive role of XBJ injection in SALI by alleviating apoptosis and inflammatory response partially through regulating the Hippo pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.